Instituto de Investigación Sanitaria de Navarra-ko ikertzaileekin lankidetzan egindako argitalpenak (42)

2024

  1. Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis

    JHEP Reports, Vol. 6, Núm. 8

  2. Comprehensive in silico CpG methylation analysis in hepatocellular carcinoma identifies tissue- and tumor-type specific marks disconnected from gene expression

    Journal of Physiology and Biochemistry

  3. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

  4. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5

  5. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)

    Clinical science (London, England : 1979), Vol. 138, Núm. 20, pp. 1265-1284

  6. Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia

  7. Sweet dreams could be made of this: carbohydrate-responsive element-binding protein (ChREBP) as a target for hepatocellular carcinoma therapy

    Molecular Oncology

2023

  1. A new FGF15/19-mediated gut-to-heart axis controls cardiac hypertrophy

    Journal of Pathology, Vol. 261, Núm. 3, pp. 335-348

  2. Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 901-924

  3. Frontiers in fatty liver: recent advances in pathogenic mechanisms, assessment of patients’ prognosis and pharmacotherapy: MASLD: new pathogenic mechanisms, risk assessment tools and drug therapies

    Journal of Physiology and Biochemistry

  4. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  5. Loss of liver function in chronic liver disease: An identity crisis

    Journal of Hepatology, Vol. 78, Núm. 2, pp. 401-414

  6. Mapping early serum proteome signatures of liver regeneration in living donor liver transplant cases

    BioFactors, Vol. 49, Núm. 4, pp. 912-927

2022

  1. Activation of the unfolded protein response (Upr) is associated with cholangiocellular injury, fibrosis and carcinogenesis in an experimental model of fibropolycystic liver disease

    Cancers, Vol. 14, Núm. 1

  2. DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

    Cancers, Vol. 14, Núm. 9

  3. Hepatic progenitor cells, senescence and IL-6 as the main players in combined hepatocellular-cholangiocarcinoma development

    Journal of Hepatology

  4. Impact of CYLD on chromatin structure and histone methylation in malignant melanoma

    International Journal of Molecular Medicine, Vol. 49, Núm. 5

  5. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734

  6. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  7. SLU7: A New Hub of Gene Expression Regulation—From Epigenetics to Protein Stability in Health and Disease

    International Journal of Molecular Sciences, Vol. 23, Núm. 21